MedTrace Logo

Spinal Hypobaric Local Anesthetic Study

NCT06166394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-03-28

No results posted yet for this study

Summary

The length of hospital stay after total hip and knee arthroplasty is determined based on the successful mobilization of the patients post surgery. Fast track pathways involving early mobilization and discharge of the patient on the same day of surgery, shortens the hospital stay and reduces the risk of adverse effects. The long acting LA (bupivacaine) is most commonly used in spinal anesthesia for arthroplasty surgeries and is associated with a prolonged motor and sensory block. In contrast, hypobaric bupivacaine and hypobaric mepivacaine helps in achieving the desired block level with smaller dosage and shorter onset time and faster recovery when compared to long acting local anesthetics. The aim of the study is to observe the effects of hypobaric local anesthetics ( bupivacaine and mepivacaine ) in patients undergoing unilateral total hip or knee arthroplasty in terms of time to onset and time to recovery of the block and also its effect on hemodynamic stability and time to mobilization after surgery. This study will allow the investigators to recommend optimal dosing strategies that in turn will help in faster recovery from spinal anesthesia and early mobilization thereby reducing harmful outcomes.

Conditions

  • Anesthesia, Local

Interventions

DRUG

Spinal hypobaric Mepivacaine Local Anesthetic Injection

• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml

DRUG

Spinal hypobaric Bupivacaine Local Anesthetic Injection

Administration of a hypobaric spinal mixture for In-patients: 3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Ki Jinn Chin, MD,FRCPC · UHN

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-09
Primary Completion
2023-10-17
Completion
2024-05-24

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06166394 on ClinicalTrials.gov